Pharmaceutical composition for treating neuropathic pain

A pharmaceutical composition targeting JAK/STAT signaling with JAK/STAT, CCL2, and MMP2 inhibitors addresses the inadequacies of current treatments for post-stroke neuropathic pain, providing long-term pain relief by modifying pain pathology in post-stroke pain model mice.

WO2024242111A1PCT designated stage expired Publication Date: 2024-11-28OSAKA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018707
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current treatments for post-stroke neuropathic pain, particularly thalamic pain, are inadequate, with no fundamental solutions and limited effectiveness from common analgesics and epilepsy drugs, and the underlying pathophysiology remains poorly understood.

Method used

A pharmaceutical composition comprising JAK/STAT inhibitors, CCL2 inhibitors, and MMP2 inhibitors is developed to treat and prevent central neuropathic pain, specifically targeting the JAK/STAT signaling pathway and associated molecular mechanisms to provide long-term therapeutic effects.

Benefits of technology

The composition effectively improves and prevents pain in post-stroke pain model mice by modifying pain pathology, offering long-term relief compared to temporary symptomatic treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000037
    Figure 000037
  • Figure 000038
    Figure 000038
  • Figure 000039
    Figure 000039
Patent Text Reader

Abstract

Disclosed is a pharmaceutical composition for treating and / or preventing central neuropathic pain, the pharmaceutical composition containing at least one component selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor. Also disclosed is a pharmaceutical composition for treating and / or preventing neuropathic pain, the pharmaceutical composition containing at least one component selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor and being to be administered at intervals of 6 days or more.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for treating neuropathic pain

[0001] The present invention relates to a pharmaceutical composition for treating and / or preventing neuropathic pain (particularly central neuropathic pain), etc.

[0002] Stroke is the fourth leading cause of death in Japan and is known to be the leading cause of requiring nursing care. Furthermore, given the social aspect of rising medical costs, providing appropriate treatment for stroke and improving prognosis is an important social issue. Once a stroke occurs, various aftereffects, such as paralysis, pain disorders, memory impairment, infections, depression, anxiety, and convulsions, often occur depending on the site of injury (Non-Patent Document 1), posing a serious problem that reduces the quality of life (QOL) of stroke sufferers. Post-stroke pain (Central Post-Stroke Pain; CPSP), a type of neuropathic pain, is caused by damage to the somatosensory pathway, which transmits external information input to sensory receptors via sensory nerves, the spinal cord, and the thalamus, and then projects to the somatosensory cortex in the parietal lobe of the cerebral cortex, due to cerebral hemorrhage or cerebral infarction. Damage to the thalamus, in particular, often causes post-stroke pain, and chronic pain following thalamic hemorrhage is intractable and presents a significant clinical problem. The incidence rate is estimated to be approximately 8-11% of stroke patients (Non-Patent Document 2). Currently, no fundamental treatment for post-stroke pain has been established, and the effectiveness of common analgesics such as non-steroidal anti-inflammatory drugs is extremely limited. Antidepressants and antiepileptic drugs are currently being tried to alleviate symptoms (Non-Patent Document 3). The underlying pathogenesis of persistent post-stroke pain has yet to be fully elucidated, and elucidation of the molecular mechanisms and the development of groundbreaking pain treatments based on these mechanisms are awaited.

[0003] AG490 is a synthetic derivative of benzylidenemalonitrile and a JAK2 (Janus kinase 2, the upstream gene of STAT3) phosphorylation inhibitor that inhibits the phosphorylation of STAT3 (Non-Patent Document 4). STAT3 is activated by JAK2 bound to the cytokine receptor complex after cytokine binding. The phosphorylation of STAT3 tyrosine residues leads to STAT homo- or heterodimerization, translocation from the cytoplasm to the nucleus, and binding to specific DNA elements (STAT recognition sites), thereby regulating target gene expression (Non-Patent Documents 5 and 6). Administration of AG490 has been reported to improve itch in chronic itch conditions (Non-Patent Document 7) and reduce neuronal cell death and neuronal dysfunction in post-ischemic cerebral infarction conditions (Non-Patent Document 8). However, no research has demonstrated the therapeutic effect of AG490 in post-stroke pain conditions.

[0004] AZD1480 is an ATP-competitive inhibitor of JAK1 and JAK2, and exerts beneficial effects in cancer models by suppressing downstream activation of STATs, particularly STAT3 (Non-Patent Documents 9 and 10). It has also been reported that administration of AZD1480 reduces STAT activation in central nervous tissue, reduces pathogenic Th1 and Th17 cell responses, alters the function of dendritic cells and macrophages, and reduces the ability of immune cells to infiltrate central nervous tissue in the pathology of autoimmune encephalomyelitis (Non-Patent Document 11). However, there have been no research reports demonstrating the therapeutic effect of AZD1480 in post-stroke pain.

[0005] Stattic is a STAT3 inhibitor that selectively inhibits STAT3 activation, dimerization, and nuclear translocation, inducing apoptosis in STAT3-dependent cancer cell lines (Non-Patent Document 12). It has been reported that administration of Stattic is effective in Alzheimer's disease, depression, and transient middle cerebral artery occlusion. However, no research has demonstrated the therapeutic effect of Stattic in post-stroke pain.

[0006] BP-1-102 is a STAT3 inhibitor that inhibits STAT3 activation, phosphorylation, and dimerization by binding to three subpockets in the SH2 domain of STAT3 (Non-Patent Document 13). It has been reported that administration of BP-1-102 is effective in ischemic stroke, glioblastoma, and intracranial aneurysm pathologies. However, no research has been reported to date demonstrating the therapeutic effect of BP-1-102 in post-stroke pain pathologies.

[0007] Watanabe, T., Tanaka, M., Watanabe, K., et al. Research and development of the free radical scavenger edaravone as a neuroprotectant. Yakugaku Zasshi; 124: 99-111 (2004).Bowsher D. Stroke and central poststroke pain in an elderly population. J Pain; 2(5):258-61 (2001).Kumar et al. Central poststrole pain: A review of pathophysiology and treatment. Anesth. Analog; 108: 1645-1657 (2009).Satriotomo I, Bowen KK, Vemuganti R. JAK2 and STAT3 activation contributes to neuronal damage following transient focal cerebral ischemia. J Neurochem 98(5):1353-1368 (2006).Brooks-Kayal AR, Raol YH, Russek SJ. Alteration of epileptogenesis genes. Neurotherapeutics 6(2):312-318 (2009).Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol 37(1-2):1-11 (2000).Shiratori-Hayashi et al. STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch. Nat Med 21(8):927-31 (2015).Pang et al.Apolipoprotein E Exerts a Whole-Brain Protective Property by Promoting M1 Microglia Quiescence After Experimental Subarachnoid Hemorrhage in Mice. Translational Stroke Research 9:654-668 (2018).Hedvat et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497 (2009).McFarland et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol. Cancer Ther. 10: 2384-2393 (2011).Liu et al. Therapeutic Efficacy of Suppressing the JAK / STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis. The Journal of Immunology. 192 (1) 59-72 (2014).Schust et al. Stattic: A Small-Molecule Inhibitor of STAT3 Activation and Dimerization. Chemistry & Biology. 1123-1124 (2006).Zhang et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. PNAS. Proc Natl Acad Sci. 109:9623-8 (2012).

[0008] An objective of the present invention is to provide a pharmaceutical composition for treating and / or preventing neuropathic pain.

[0009] As a result of extensive research aimed at achieving the above-mentioned objectives, the present inventors have discovered that administering JAK / STAT inhibitors, such as AG490, AZD1480, Stattic, and BP-1-102, to a mouse model of post-stroke pain can improve pain and even prevent its onset. Existing drugs are all symptomatic treatments, not so-called disease-modifying drugs, and their effects are only temporary. In contrast, the present invention provides long-term therapeutic effects, demonstrating that JAK / STAT inhibitors provide long-term therapeutic effects by modifying the pain pathology. Furthermore, it has been confirmed that knockout of CCL2 and administration of an MMP2 inhibitor can also improve pain in a mouse model of post-stroke pain, similar to JAK / STAT inhibitors.

[0010] The present invention was completed based on these findings and through further investigation, and provides the following pharmaceutical composition.

[0011] Item 1. A pharmaceutical composition for treating and / or preventing central neuropathic pain, comprising at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor. Item 2. The pharmaceutical composition according to Item 1, comprising a JAK / STAT inhibitor. Item 3. The pharmaceutical composition according to Item 1, wherein the central neuropathic pain is pain caused by a brain disorder. Item 4. The pharmaceutical composition according to Item 1, wherein the central neuropathic pain is post-stroke pain. Item 5. The pharmaceutical composition according to Item 1, wherein the central neuropathic pain is thalamic pain. Item 6. The pharmaceutical composition according to any one of Items 1 to 5, wherein the STAT is STAT3. Item 7. Item 7. The pharmaceutical composition according to any one of Items 1 to 6, wherein the JAK / STAT inhibitor is at least one selected from the group consisting of a STAT3 SH2 domain inhibitor, a JAK inhibitor, a STAT3 DNA-binding domain inhibitor, double-stranded RNA having an RNAi effect on the JAK or STAT3 gene, and an antisense nucleic acid against the JAK or STAT3 gene. Item 8. The pharmaceutical composition according to any one of Items 1 to 7, wherein the JAK / STAT inhibitor is at least one selected from the group consisting of a STAT3 SH2 domain inhibitor and a JAK inhibitor. Item 9. A pharmaceutical composition for treating and / or preventing neuropathic pain, comprising at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor, the administration interval of which is 6 days or more. Item 10. The pharmaceutical composition according to Item 9, comprising a JAK / STAT inhibitor. Item 11. Item 11. A method for treating and / or preventing central neuropathic pain, comprising the step of administering at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor to a mammal in need of said treatment and / or prevention. Item 12. A method for treating and / or preventing neuropathic pain, comprising the step of administering at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor to a mammal in need of said treatment and / or prevention at an administration interval of 6 days or more. Item 13. Use of at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor in the manufacture of a pharmaceutical composition for treating and / or preventing central neuropathic pain.Item 14. Use of at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor in the manufacture of a pharmaceutical composition for the treatment and / or prevention of neuropathic pain, wherein the administration interval of the pharmaceutical composition is 6 days or longer.

[0012] The pharmaceutical composition of the present invention is capable of treating and preventing neuropathic pain (particularly central neuropathic pain).

[0013] 1 is a graph showing the results of investigating the effects of administration of AG490 and AZD1480 on pain in a mouse model of chronic post-stroke pain. The legend in the figure is as follows. TH: thalamic hemorrhage, vehicle: vehicle-administered group as a control group for the drug groups. Values ​​are mean ± standard error. n=7 for each group, *p<0.0001 (both vs. TH / vehicle group; 2-way ANOVA, Sidak test). 1 is a graph showing the results of investigating the effects of Stattic on pain in a mouse model of chronic post-stroke pain. The legend in the figure is as follows. TH: thalamic hemorrhage, vehicle: vehicle-administered group as a control group for the drug groups. Values ​​are mean ± standard error. n=6 for each group, *p<0.0001 (2-way ANOVA, Sidak test). 1 is a graph showing the results of investigating the effect of BP-1-102 on pain in a mouse model of post-stroke pain in the chronic phase. The legend in the figure is as follows. TH: thalamic hemorrhage, vehicle: vehicle-administered group as a control group for the drug group. Values ​​are mean ± standard error. Control group (TH / vehicle group) n = 6, BP-1-102-administered group n = 8, *<0.0001 (2-way ANOVA, Sidak test). This graph shows the results of investigating the effect of BP-1-102 on pain in a mouse model of post-stroke pain in the ultra-chronic phase. The legend in the figure is as follows. TH: thalamic hemorrhage. Values ​​are mean ± standard error. BP-1-102-administered group n = 4. In the graph below, the average values ​​from 74 to 81 days after hemorrhage are taken as pre-administration values, and the average values ​​from 98 to 105 days after hemorrhage are taken as post-administration values. ***p<0.0001 (Paired t test) This graph shows the results of investigating the effect on pain caused by administration of AG490 in the early stage of thalamic hemorrhage. The legend in the figure is as follows: TH: thalamic hemorrhage. n=6, values ​​are mean ± standard error. This graph shows the results of investigating the effect on pain caused by an existing JAK inhibitor (baricitinib) in the chronic phase of post-stroke pain model mice. The legend in the figure is as follows: TH: thalamic hemorrhage. Values ​​are mean ± standard error. Baricitinib administration group, n=4.Figure 1 shows the results of an investigation into the effect on pain caused by direct administration of an astrocyte activation inhibitor (fluorocitric acid) to the S1 region of the cerebral cortex in a chronic-phase post-stroke pain model mouse. The legend in the figure is as follows: TH: thalamic hemorrhage; vehicle: vehicle-administered group as a control group for the drug group. Values ​​are means ± standard error. Control group (TH / vehicle group) n = 4; fluorocitric acid-administered group n = 5. *p < 0.05, ****p < 0.0001 (2-way ANOVA, Sidak test). Figure 1 shows the results of an investigation into the effect on pain caused by direct administration of a STAT3 inhibitor (BP-1-102) to the S1 region of the cerebral cortex in a chronic-phase post-stroke pain model mouse. The legend in the figure is as follows: TH: thalamic hemorrhage; vehicle: vehicle-administered group as a control group for the drug group. Values ​​are means ± standard error. Control group (TH / vehicle group) n=5, BP-1-102 administration group n=6. **p<0.01, ***p<0.001, ***p<0.0001 (2-way ANOVA, Sidak test). This graph shows the results of investigating the effect of astrocyte-specific CCL2 knockout on pain in the chronic phase of a post-stroke pain model mouse. The legend in the figure is as follows: Control group: Aldh1l1-CreERT2- / -::CCL2 flox / flox group. Values ​​are means ± standard error. Each group n=7. *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001 (2-way ANOVA, Sidak test). This graph shows the results of investigating the effect on pain caused by intracerebroventricular administration of the MMP2-selective inhibitor ARP100 in a chronic-phase post-stroke pain model mouse. The legend in the figure is as follows: TH: thalamic hemorrhage, vehicle: vehicle-administered group as a control group for the drug group. Values ​​are means ± standard error. n=5 per group. *p<0.05, **p<0.01 (Mixed-effects model, Sidak test). This graph shows the results of investigating the effect on pain caused by astrocyte-specific STAT3 knockout in a chronic-phase post-stroke pain model mouse. Values ​​are means ± standard error.Aldh1l1-CreERT2- / -::STAT3 flox / flox group (control group) n=1, Aldh1l1-CreERT2+ / -::STAT3 flox / flox group n=7. This graph shows the results of investigating the effect of astrocyte-specific STAT3 knockout on pain in the S1 region of the cerebral cortex on the side of thalamic hemorrhage in the chronic phase of post-stroke pain model mice. Values ​​are means ± standard error. AAV5-GFAP-GFP-Cre (male) n=3, AAV5-GFAP-GFP (male) n=2, AAV5-GFAP-GFP-Cre (female) n=3, AAV5-GFAP-GFP (female) n=3.

[0014] Hereinafter, embodiments of the present invention will be described in detail.

[0015] In the present invention, "nucleic acid" means RNA or DNA. In the present invention, unless otherwise specified, "gene" includes double-stranded DNA, single-stranded DNA (sense strand or antisense strand), and fragments thereof. Furthermore, in the present invention, "gene" refers to regulatory regions, coding regions, exons, and introns without distinction, unless otherwise specified.

[0016] As used herein, the terms "JAK," "STAT," "CCL2," and "MMP2" refer to proteins or genes, and when it is appropriate to interpret them as proteins, they refer to proteins, and when it is appropriate to interpret them as genes, they refer to genes.

[0017] In the present invention, the terms "nucleic acid," "nucleotide," and "polynucleotide" are synonymous and include both DNA and RNA, and may be double-stranded or single-stranded.

[0018] The pharmaceutical composition of the present invention comprises at least one inhibitor (preferably a JAK / STAT inhibitor) selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor, and is characterized by being used for the treatment and / or prevention of central neuropathic pain.

[0019] In another embodiment, the pharmaceutical composition of the present invention is for the treatment and / or prevention of neuropathic pain, comprises at least one inhibitor (preferably a JAK / STAT inhibitor) selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor, and is administered at an interval of 6 days or more.

[0020] Neuropathic pain is defined as pain that occurs as a direct result of damage or disease to the somatosensory system (the nerves that transmit pain), and is classified as central neuropathic pain or peripheral neuropathic pain.

[0021] Central neuropathic pain is pain caused by central nervous system lesions and refers to unbearable pain deep in the body. Central neuropathic pain is pain caused by damage (injury) to the brain and spinal cord (particularly the brain), with the brain and spinal cord (particularly the brain) being the responsible lesion. The responsible lesion is preferably the thalamus. Examples of central neuropathic pain include post-stroke pain, post-traumatic spinal cord injury pain, pain due to multiple sclerosis, compressive myelopathy due to spinal canal stenosis, pain associated with Parkinson's disease, HIV myelopathy, post-ischemic myelopathy, post-radiation myelopathy / post-radiation encephalopathy, syringomyelia / syringobulbar syndrome, etc. Among these, post-stroke pain is preferred, and thalamic pain is particularly preferred. Among post-stroke pain and thalamic pain, pain due to bleeding is more preferred.

[0022] In the present invention, "JAK / STAT inhibitor" refers to any compound capable of inhibiting the JAK / STAT signaling pathway, and examples of such compounds include compounds that inhibit or suppress the expression of JAK and / or STAT, and compounds that inhibit or reduce the function or activity of JAK and / or STAT. The "JAK / STAT inhibitor" may be a compound that inhibits either SJAK or STAT, or may be a compound that inhibits both JAK and STAT. Furthermore, the "JAK / STAT inhibitor" is preferably a compound that has high central nervous system penetration and minimal effect on peripheral nerves.

[0023] Four types of JAKs are known: JAK1, JAK2, JAK3, and Tyk2. Furthermore, STATs (signal transducers and activators of transcription) include STAT1, STAT2, STAT3, STAT4, STAT5, and STAT6, with STAT3 being preferred.

[0024] Examples of JAK / STAT inhibitors include low molecular weight compounds, medium molecular weight compounds, antibodies, antibody fragments, nucleic acids, etc., which have an inhibitory effect on the JAK / STAT signaling pathway. SJAK / STAT inhibitors can be used alone or in combination of two or more.

[0025] Examples of JAK / STAT inhibitors include STAT3 SH2 domain inhibitors, JAK inhibitors (e.g., STAT3 phosphorylation inhibitors), STAT3 DNA binding domain inhibitors, double-stranded RNA having an RNAi effect on the JAK or STAT3 gene, and antisense nucleic acids against the JAK or STAT3 gene, and preferred are STAT3 SH2 domain inhibitors and JAK inhibitors.

[0026] STAT3 SH2 domain inhibitors inhibit the SH2 domain and have the function of inhibiting the formation of STAT3 homo- or heterodimers. Examples of STAT3 SH2 domain inhibitors include Stattic, BP-1-102, STA-21, C188-9, S3I-201, YHO-1701, STX-0119, LLL12B, and LL1. JAK inhibitors have the function of inhibiting JAK (for example, those having the function of inhibiting JAK-mediated phosphorylation of STAT3). The JAK inhibitor may be one that inhibits any of JAK1, JAK2, JAK3, and Tyk2, and examples thereof include AZD1480, AG490, ruxolitinib, tofacitinib, baricitinib, peficitinib, upadacitinib, filgotinib, delgocitinib, abrocitinib, etc. The STAT3 DNA-binding domain inhibitor has the function of inhibiting STAT3 that has translocated into the nucleus from binding to DNA. Examples of STAT3 DNA binding domain inhibitors include CPA-1, CPA-7, inS3-54A18, and the like.

[0027] As the JAK / STAT inhibitor, an antibody or antibody fragment having an inhibitory effect on the JAK / STAT signaling pathway can be used. Examples of antibody fragments having antigen-binding activity against proteins involved in JAK, STAT, and other signaling pathways include Fd, Fv, Fab, F(ab'), and F(ab) 2 , F(ab') 2Examples of antibodies include single-chain Fvs (scFvs), diabodies, triabodies, tetrabodies, and minibodies. Examples of antibodies include those derived from animals such as mice, rats, cows, rabbits, goats, sheep, and guinea pigs. The antibody isotype is not particularly limited, and examples of isotypes include IgG (IgG1, IgG2, IgG3, and IgG4), IgA, IgD, IgE, and IgM. The antibody may be either a monoclonal or polyclonal antibody, preferably a monoclonal antibody. The antibody may also be a humanized antibody, a chimeric antibody, or a multispecific antibody (e.g., a bispecific antibody). Antibodies can be produced by known methods, such as by constructing an expression vector containing a nucleic acid encoding the antibody, culturing a transformant into which the nucleic acid has been introduced, or culturing a hybridoma that produces the antibody.

[0028] Examples of nucleic acids having an inhibitory effect on the JAK / STAT signaling pathway include double-stranded RNAs (e.g., siRNA (small interfering RNA), shRNA (small hairpin RNA), and dsRNA (double-stranded RNA)) that have an RNAi effect on JAK and / or STAT genes (including their transcription products), and antisense nucleic acids against JAK and / or STAT genes (including their transcription products). Furthermore, expression vectors that express such siRNA, shRNA, dsRNA, and antisense nucleic acids can also be used.

[0029] siRNA is a double-stranded oligo-RNA consisting of an RNA having a sequence complementary to the nucleotide sequence of mRNA of a target gene or a partial sequence thereof (target nucleotide sequence) and its complementary strand. Also included in siRNA are single-stranded RNAs in which a sequence complementary to the target nucleotide sequence (first sequence) is linked to its complementary sequence (second sequence) via a hairpin loop portion, in which the first sequence forms a double-stranded structure with the second sequence by adopting a hairpin loop structure (shRNA), and dumbbell-shaped nucleic acids in which both ends of the double-stranded structure of the first sequence and the second sequence are closed by loop structures.

[0030] The siRNA may have an overhang at the 5'-end or 3'-end of one or both of the sense strand and the antisense strand. The overhang is formed by adding one to several (e.g., 1, 2, or 3) bases to the end of the sense strand and / or the antisense strand. The base length of the siRNA is not particularly limited as long as it can induce RNA interference, and may be, for example, 10 to 50 bases, 15 to 30 bases, or 21 to 27 bases per strand.

[0031] The siRNA targets mRNA encoding JAK and / or STAT, and can be designed based on the base sequence of the mRNA. The sequence is not particularly limited as long as it can induce RNA interference. The siRNA can be chemically synthesized using known techniques or produced using genetic recombination techniques.

[0032] The dsRNA has an RNAi effect and is typically a dsRNA consisting of a sense RNA with a sequence identical to any contiguous RNA region in JAK or STAT mRNA, and an antisense RNA with a sequence complementary to the sense RNA. The length of the "any contiguous RNA region" is typically 20 to 30 bases, preferably 21 to 23 bases.

[0033] The sequence of the antisense nucleic acid is preferably complementary to the target gene or a portion thereof, but does not need to be completely complementary as long as it can effectively suppress gene expression. It is sufficient for the sequence to be preferably 90% or more complementary, more preferably 95% or more complementary, to the transcription product of the target gene. To effectively suppress target gene expression using antisense nucleic acids, the length of the antisense nucleic acid is preferably 15 bases or more. Furthermore, to avoid nonspecific effects, it is preferable to use multiple antisense nucleic acids complementary to different sequences of the target gene. The antisense nucleic acid of the present invention also includes nucleic acids containing antisense sequences of not only the translated region of the target gene but also the untranslated region.

[0034] Other known JAK / STAT inhibitors include CP690550 (CAS 540737-29-9), Cpd188 (CAS 823828-18-8), 5,15-DPP (CAS 22112-89-6), WP1066 (CAS 857064-38-1), Ethyl-1-(4-cyano-2,3,5,6-tetrafluorophenyl)-6,7,8-trifluoro-4-oxo-1,4-dihydroquinone-3-carboxylate (CAS 1041438-68-9), 4-(N-(4-Cyclohexylbensyl)-2-(2,3,4,5,6-pentaf luoro-N-methylphenylsulfonamido)acetamido)-2-Hydroxybenzoic acid, 5-Hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide, N-(5-(Furan-2-y l)-1,3,4-oxadiazol-2-yl)-2-phenylquinoline-4-carboxamide, 17-Hydroxy-jolkinolide B, N-(1',2-Dihydroxy-1,2'-binaphthalen-4'-yl)-4-methoxybenzenesulfonamide (F1113-0789), arylsulfonamidyl thiophene Amide and the like are known.

[0035] In the present invention, the term "CCL2 inhibitor" refers to any compound capable of inhibiting CCL2 (C-C motif chemokine ligand 2), and examples of such compounds include compounds that inhibit or suppress the expression of CCL2, and compounds that inhibit or reduce the function or activity of CCL2. Furthermore, the "CCL2 inhibitor" is preferably a compound that has high central nervous system delivery and minimal effect on peripheral nerves. CCL2 is a cytokine that belongs to the CC chemokine family, and is also known as MCP-1 (monocyte chemoattractant protein-1), etc.

[0036] Examples of CCL2 inhibitors include low molecular weight compounds, medium molecular weight compounds, antibodies, antibody fragments, nucleic acids, etc., which have a CCL2 inhibitory effect. One CCL2 inhibitor can be used alone, or two or more CCL2 inhibitors can be used in combination.

[0037] Examples of CCL2 inhibitors include bindarit, propagermanium, dominant-negative mutants of CCL2, antibodies or antibody fragments against CCL2, double-stranded RNAs having an RNAi effect on the CCL2 gene, antisense nucleic acids against the CCL2 gene, etc. The above descriptions regarding antibodies or antibody fragments, double-stranded RNAs, and antisense nucleic acids apply.

[0038] In the present invention, the term "MMP2 inhibitor" refers to any compound capable of inhibiting MMP2 (matrix metalloproteinase-2), and examples of such compounds include compounds that inhibit or suppress the expression of MMP2, and compounds that inhibit or reduce the function or activity of MMP2. Furthermore, the "MMP2 inhibitor" is preferably a compound that has high central nervous system penetration and minimal effect on peripheral nerves. MMP2 belongs to the MMP family and is an enzyme that degrades extracellular matrix as a substrate, and is also known as 72 kDa type IV collagenase.

[0039] Examples of MMP2 inhibitors include low molecular weight compounds, medium molecular weight compounds, antibodies, antibody fragments, nucleic acids, etc., which have an MMP2 inhibitory effect. The MMP2 inhibitors can be used alone or in combination of two or more.

[0040] Examples of MMP2 inhibitors include ARP100, ARP101, SB-3CT, Ilomastat (GM6001), Batimstat (BB-94), Marimstat (BB-2516), Solasodine, MMP2-IN-3, BPHA, MMP-2 Inhibitor I, II, III, IV, dominant-negative mutants of MMP2, antibodies or antibody fragments against MMP2, double-stranded RNA having an RNAi effect on the MMP2 gene, antisense nucleic acids against the MMP2 gene, etc. The above descriptions regarding antibodies or antibody fragments, double-stranded RNA, and antisense nucleic acids apply.

[0041] As the JAK / STAT inhibitors, CCL2 inhibitors, and MMP2 inhibitors, JAK / STAT inhibitors, CCL2 inhibitors, and MMP2 inhibitors that will be newly developed in the future can also be used in the present invention.

[0042] The JAK / STAT inhibitors, CCL2 inhibitors, and MMP2 inhibitors can be used in their free form or in the form of a salt. Examples of salts include salts with inorganic bases such as sodium salts, potassium salts, calcium salts, magnesium salts, and aluminum salts; salts with organic bases such as methylamine, ethylamine, and ethanolamine; salts with basic amino acids such as lysine, arginine, and ornithine; and ammonium salts. The salts may be acid addition salts, including salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid. Furthermore, the JAK / STAT inhibitors, CCL2 inhibitors, and MMP2 inhibitors also include their hydrates, solvates, crystalline polymorphs, and the like.

[0043] The contents of the JAK / STAT inhibitor, CCL2 inhibitor, and MMP2 inhibitor in the pharmaceutical composition of the present invention may be, for example, 0.001 to 100% by mass of the total amount of the pharmaceutical composition, with the upper or lower limit of this range being, for example, 0.01%, 0.1%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.9% by mass.

[0044] In addition to the JAK / STAT inhibitor, CCL2 inhibitor, and MMP2 inhibitor, the pharmaceutical composition of the present invention may contain, as needed, pharmaceutically acceptable ingredients such as excipients, binders, disintegrants, lubricants, colorants, suspending agents, thickeners, antioxidants, absorption enhancers, pH adjusters, preservatives, antiseptics, stabilizers, surfactants, sweeteners, flavoring agents, and fragrances.

[0045] Examples of excipients include lactose, sucrose, refined sucrose, D-mannitol, D-sorbitol, corn starch, potato starch, dextrin, crystalline cellulose, sodium carboxymethylcellulose, light anhydrous silicic acid, talc, and kaolin.

[0046] Examples of binders include pregelatinized starch, gelatin, gum arabic, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, sucrose, refined sucrose, pullulan, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.

[0047] Examples of disintegrants include lactose, sucrose, corn starch, potato starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, alginic acid, and crospovidone.

[0048] Examples of lubricants include stearic acid, magnesium stearate, calcium stearate, talc, and polyethylene glycol.

[0049] Examples of colorants include iron sesquioxide, yellow iron sesquioxide, brown iron oxide, black iron oxide, and titanium oxide.

[0050] Examples of suspending agents include polysorbate, polyethylene glycol, and glycerin.

[0051] Examples of dosage forms of the pharmaceutical composition include tablets (including plain tablets, sugar-coated tablets, effervescent tablets, film-coated tablets, chewable tablets, troches, etc.), capsules, pills, powders (pulverized medicines), granules, fine granules, liquids, suspensions, emulsions, pastes, syrups, injections (including cases where the composition is mixed with distilled water or an infusion such as an amino acid infusion or an electrolyte infusion at the time of use to prepare a liquid), etc. These preparations can be manufactured according to conventional methods.

[0052] The method of administration of the pharmaceutical composition of the present invention is not particularly limited and may be local or systemic. The administration route may be, for example, intra-arterial, intravenous, subcutaneous, intraperitoneal, intramuscular, rectal, intrathecal, or oral.

[0053] The pharmaceutical composition of the present invention is administered to mammals, including humans.

[0054] The dosage of the pharmaceutical composition of the present invention can be determined appropriately depending on various conditions such as the patient's weight, age, sex, and symptoms.

[0055] The administration period of the pharmaceutical composition of the present invention is not particularly limited, and a preferable period can be selected while observing the condition of the patient. The withdrawal period of the pharmaceutical composition of the present invention is also not particularly limited, and a preferable period can be selected while observing the condition of the patient.

[0056] The administration interval of the pharmaceutical composition of the present invention is not particularly limited, and examples thereof include daily administration, every other day administration, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, 14 days or more, 15 days or more, 16 days or more, 17 days or more, 18 days or more, 19 days or more, 20 days or more, 30 days or more, 40 days or more, and 50 days or more. Alternatively, the pharmaceutical composition of the present invention may be administered only once, without multiple administrations. As shown in the examples below, a literature on peripheral neuropathic pain (Brain. 134(4):1127-1139 (2011)) describes that the effect of a JAK / STAT inhibitor disappears promptly (at least 3 days) after administration, whereas the examples show that the effect of the pharmaceutical composition of the present invention persists for at least 2 weeks or more after administration. This suggests that even if the same JAK / STAT inhibitor is used, the mechanism of action differs between central neuropathic pain and peripheral neuropathic pain.

[0057] As shown in the Examples below, administration of JAK / STAT inhibitors such as AG490, AZD1480, Stattic, BP-1-102, and baricitinib to a mouse model of post-stroke pain has been shown to improve pain and even prevent the onset of pain, indicating that JAK / STAT inhibitors are effective against central neuropathic pain. Furthermore, knocking out CCL2 and administering the MMP2 inhibitor ARP100 to a mouse model of post-stroke pain have been shown to improve pain, indicating that CCL2 inhibitors and MMP2 inhibitors are also effective against central neuropathic pain.

[0058] All existing drugs are symptomatic and cannot be considered so-called disease-modifying drugs, and their effects are temporary. In contrast, the present invention provides long-term therapeutic effects, demonstrating that JAK / STAT inhibitors, CCL2 inhibitors, and MMP2 inhibitors provide long-term therapeutic effects by modifying pain pathology. Existing drugs are used for both peripheral and central neuropathic pain, but this is because they are symptomatic. The pharmaceutical composition of the present invention aims to alleviate the molecular pathology of central neuropathic pain itself, and its treatment strategy is clearly different from that of existing drugs.

[0059] As described above, the pharmaceutical composition of the present invention is useful for treating and preventing neuropathic pain (particularly central neuropathic pain).

[0060] In this specification, the term "comprising" includes "consisting essentially of" and "consisting of."

[0061] Furthermore, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present invention may be combined in any way to specify the subject matter encompassed by the present invention, i.e., the present invention encompasses all subject matter consisting of any combination of the combinable characteristics described herein.

[0062] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.

[0063] 1-1 Experimental Method (1) Preparation of Post-Stroke Pain Model An intracerebral collagenase injection model was used as a post-stroke pain model. Under mixed anesthesia with medetomidine chloride (0.3 mg / kg; Orion Pharma), midazolam (4 mg / kg; Astellas Pharma Inc.), and butorphanol (5 mg / kg; Vetorphale, Meiji Seika Pharma Co., Ltd.), thalamic hemorrhage was induced by injecting 0.025 U collagenase type IV (MilliporeSigma, C5138) dissolved in PBS at the stereotaxic coordinates of the thalamic hemorrhage group. Based on previous research (Hanada et al., Development and pharmacological verification of a new mouse model of central post-stroke pain. Neurosci Res. 78:72-80 (2014)), a custom-made cannula was inserted at the following coordinates: 1.1 mm posterior to bregma, 1.5 mm lateral from the midline, and 3.5 mm ventral from the cortical surface. A total of 25 nL of collagenase was injected into the ventral posterolateral nucleus of the thalamus through the tubing. The cannula was connected to a 25 μL gastight syringe (Hamilton, 80200) and infused at a constant rate of 5 nL / min using an infusion pump (Eicom, ESP-32).

[0064] (2) Measurement of pain-related behaviors. The von Frey test was performed to measure responses to mechanical stimuli. A plastic case was placed on top of a wire mesh, and the pain model mice were placed inside the case and allowed to settle for 10 to 30 minutes. Mechanical stimuli were applied to both hind paws of each mouse using 0.02 to 2 g monofilaments (Semmes-Weinstein von Frey Anesthesiometer; Muromachi Kikai Co., Ltd.), and the 50% withdrawal threshold was determined using the up-down method (Chaplan et al., Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 53(1):55-63 (1994)).

[0065] (3) Chronic Administration Experiment of AG490 Thalamic hemorrhage was induced in 10-13 week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate mice with post-stroke pain. Von Frey tests were performed before the induction of thalamic hemorrhage and 1, 4, 7, 11, 14, 18, and 21 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. AG490 (Tyrphostin B42, Zinc 02557947; Selleck Biotech Co., Ltd.) was diluted with 5% Dimethyl sulfoxide (Sigma-Aldrich; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries, Ltd.; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), 50% dH 2 AG490 was dissolved in 0 mL of 100 mL of 1% ethanol at a concentration of 3 mg / mL. Before administration, the mice were weighed, and 10 μg / g of AG490 was intraperitoneally administered to the mice. The von Frey test was performed 24 and 48 hours after administration and on days 4, 7, 11, and 14 to examine changes in the withdrawal threshold.

[0066] (4) AG490 Administration Experiment in the Early Stage of Onset Thalamic hemorrhage was induced in 10-week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate post-stroke pain mice. Pain thresholds were measured using the von Frey test before, 1, 4, 7, 11, and 14 days after the induction of thalamic hemorrhage. AG490 was administered intraperitoneally immediately after the induction of thalamic hemorrhage, and 4, 7, and 11 days after the induction, and after the von Frey test.

[0067] (5) Chronic Administration Experiment of AZD1480 Thalamic hemorrhage was induced in 9-10 week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate mice with post-stroke pain. Von Frey tests were performed before the induction of thalamic hemorrhage and 1, 4, 7, 11, 14, and 21 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. AZD1480 (S2162; Selleck Biotech Co., Ltd.) was diluted with 5% dimethyl sulfoxide (Sigma-Aldrich Co., Ltd.; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries, Ltd.; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), and 50% dH 2 AZD1480 was dissolved in 0 to a concentration of 5 mg / mL. Before administration, the mice were weighed, and 30 μg / g of AZD1480 was intraperitoneally administered to the mice. 24 and 48 hours after administration, and on days 4, 7, 11, and 14, the von Frey test was performed to examine changes in the withdrawal threshold.

[0068] (6) Chronic Administration Experiment of Stattic Thalamic Hemorrhage was induced in 9-10 week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate mice with post-stroke pain. Von Frey tests were performed before the induction of thalamic hemorrhage and 1, 4, 7, 11, 14, and 21 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. Static (S7024; Selleck Biotech Co., Ltd.) was diluted with 5% dimethyl sulfoxide (Sigma-Aldrich; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries, Ltd.; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), 50% dH 2 Stattic was dissolved in 0 to a concentration of 5 mg / mL. Before administration, the mice were weighed, and 25 μg / g of Stattic was administered intraperitoneally to the mice. 24 and 48 hours after administration, and on days 4, 7, and 14, a von Frey test was performed to examine changes in the withdrawal threshold.

[0069] (7) Chronic Administration Experiment of BP-1-102 Thalamic hemorrhage was induced in 10-week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate mice with post-stroke pain. Von Frey tests were performed before the induction of thalamic hemorrhage and 1, 4, 7, 11, 14, 18, and 21 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. BP-1-102 (S7769; Selleck Biotech Co., Ltd.) was diluted with 5% dimethyl sulfoxide (Sigma-Aldrich; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries, Ltd.; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), and 50% dH 2 BP-1-102 was dissolved in 0 mL of 10 ...BP-1-102 to a concentration of 5 mg / mL. Before administration, the mice were weighed, and 25 μg / g of BP-1-102 was administered intraperitoneally to the mice. The von Frey test was performed 24 and 48 hours after administration, and thereafter up to 70 days, as shown in Figure 3, to examine changes in the withdrawal threshold.

[0070] (8) BP-1-102 Administration Experiment in the Ultra-Chronic Phase Thalamic hemorrhage was induced in 10-week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate post-stroke pain mice. Von Frey tests were performed before the induction of thalamic hemorrhage and 1, 4, 7, 11, 14, 18, 21, 25, 28, 32, 35, 39, 42, 46, 49, 53, 56, 60, 63, 67, 70, 74, 77, 81, 84, 88, and 91 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. BP-1-102 (S7769; Selleck Biotech Co., Ltd.) was diluted with 5% dimethyl sulfoxide (Sigma-Aldrich; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries, Ltd.; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), and 50% dH 2BP-1-102 was dissolved in 0 to a concentration of 5 mg / mL. Before administration, the body weight of the mice was measured, and 25 μg / g of BP-1-102 was administered intraperitoneally to the mice. 24 and 48 hours after administration, the von Frey test was performed, and changes in the withdrawal threshold were examined for 70 days after administration.

[0071] (9) Chronic Administration Experiment of Baricitinib Thalamic hemorrhage was induced in 9-week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate mice with post-stroke pain. Von Frey tests were performed before the induction of thalamic hemorrhage and 1, 4, 7, 11, 14, 18, 21, 25, 28, and 29 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. Baricitinib (S2851; Selleck Biotech) was diluted with 5% dimethyl sulfoxide (Sigma-Aldrich; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), and 50% dH 2 The mice were dissolved in 0 mL of baricitinib to a concentration of 0.8 mg / mL. Immediately before administration, the mice were weighed, and 2 μg / g of baricitinib was administered intraperitoneally. The von Frey test was performed 24 and 48 hours after administration, and changes in the escape threshold were examined for 111 days after administration. Furthermore, on day 32 after administration, when a decrease in the drug efficacy was observed, baricitinib was administered again. Immediately before administration, the mice were weighed, and 0.2 μg / g of baricitinib was administered intraperitoneally to the mice for 5 consecutive days.

[0072] (10) Chronic Phase Experiment of Fluorocitrate Administration to the S1 Region of the Cerebral Cortex Thalamic hemorrhage was induced in 9-week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate mice with post-stroke pain. von Frey tests were performed before the induction of thalamic hemorrhage and 1, 7, and 21 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. DL-Fluorocitrate barium salt (SIGMA-ALDRICH; F9634) was dissolved to a concentration of 1 nM in 0.1 mM hydrochloric acid (FUJIFILM Wako Pure Chemical Industries, Ltd.; 080-01066), 0.1 mM sodium sulfate (FUJIFILM Wako Pure Chemical Industries, Ltd.; 197-03345), 0.1 mM disodium hydrogen phosphate (FUJIFILM Wako Pure Chemical Industries, Ltd.; 197-02865), and physiological saline (Otsuka Pharmaceutical Factory, Inc.; 1326). Mice were immobilized in WPI Mouse Stereotaxic Instruments (World Precision Instruments; 505314) under mixed anesthesia with medetomidine chloride (0.3 mg / kg; Orion Pharma), midazolam (4 mg / kg; Astellas Pharma Inc.), and butorphanol (5 mg / kg; Vetorphale, Meiji Seika Pharma Co., Ltd.). A Nanoliter Glass Capillary (World Precision Instruments; 504949) was connected to a NANOLITER 2020 INJECTOR (World Precision Instruments; NANOLITER 2020) and inserted at the following coordinates: 0.35 mm posterior to bregma, 1.5 mm lateral from the midline, and 0.5 mm ventral from the cortical surface. A total of 1 μL was injected at a constant rate of 50 nL / min. Von Frey tests were performed 24 and 48 hours after administration, and changes in withdrawal thresholds were examined for 42 days after administration.

[0073] (11) Chronic Phase Experiment of BP-1-102 Administration to the S1 Region of the Cerebral Cortex Thalamic hemorrhage was induced in 10-week-old C57BL / 6J (CLEA Japan, Inc.) mice to generate mice with post-stroke pain. von Frey tests were performed before and 1, 4, 7, 11, 14, 18, and 21 days after the hemorrhage, and mice in which pain was confirmed to be induced by the thalamic hemorrhage were used for subsequent experiments. BP-1-102 (Selleck Biotech Co., Ltd.; S7769) was diluted with 5% dimethyl sulfoxide (Sigma-Aldrich Co., Ltd.; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries, Ltd.; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), 50% dH 2 The solution was dissolved in 0 to a concentration of 5 mg / mL. Mice were immobilized in WPI Mouse Stereotaxic Instruments (World Precision Instruments; 505314) under mixed anesthesia with medetomidine chloride (0.3 mg / kg; Orion Pharma), midazolam (4 mg / kg; Astellas Pharma Inc.), and butorphanol (5 mg / kg; Vetorphale, Meiji Seika Pharma Co., Ltd.). A Nanoliter Glass Capillary (World Precision Instruments; 504949) was connected to a NANOLITER 2020 INJECTOR (World Precision Instruments; NANOLITER 2020) and inserted at the following coordinates: 0.35 mm posterior to bregma, 1.5 mm lateral from the midline, and 0.5 mm ventral from the cortical surface. A total of 1 μL was injected at a constant rate of 50 nL / min. Von Frey tests were performed 24 and 48 hours after administration, and changes in withdrawal thresholds were examined for 21 days after administration.

[0074] (12) Chronic Astrocyte-Specific CCL2 Knockout Experiments: Aldh1l1-CreERT2 mice (B6N.FVB-Tg(Aldh1l1-CreERT2)1Khakh / J), which express the recombinant Cre protein specifically in astrocytes and translocate into the cell nucleus upon tamoxifen administration, were crossed with CCL2 flox mice (B6.Cg-Ccl2tm1.1Pame / J; The Jackson Laboratory; 016849), in which CCL2 is knocked out due to the presence of Cre in the cell nucleus. The resulting Aldh1l1-CreERT2+ / -::CCL2 flox / flox mice were induced with thalamic hemorrhage at 9 to 13 weeks of age to generate post-stroke pain mice. Aldh1l1-CreERT2- / -::CCL2 flox / flox was used as a control group. Tamoxifen administration in the control group is unlikely to result in CCL2 knockout. Von Frey tests were performed before thalamic hemorrhage induction and 7, 14, and 21 days after hemorrhage. Animals in which pain induction due to thalamic hemorrhage was confirmed were used for subsequent experiments. Tamoxifen (SIGMA-ALDRICH; T5648) was dissolved in corn oil (SIGMA-ALDRICH; C8297) to a concentration of 5 mg / mL. Mice were weighed immediately before tamoxifen administration, and 75 μg / g tamoxifen was administered intraperitoneally for 5 days. Von Frey tests were performed starting 7 days after the start of administration, and changes in withdrawal thresholds were monitored for 39 days after administration.

[0075] (13) Experimental study of intracerebroventricular administration of matrix metalloproteinase 2 (MMP2) selective inhibitor ARP100 in the chronic phase. Thalamic hemorrhage was induced in 11-week-old C57BL / 6J mice (CLEA Japan, Inc.) to generate mice with post-stroke pain. von Frey tests were performed before induction of thalamic hemorrhage and 1, 4, 7, 11, 14, 18, and 21 days after hemorrhage. Mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. ARP100 (S9909; Selleck Biotech Co., Ltd.) was diluted with 5% dimethyl sulfoxide (Sigma-Aldrich; D8418-100ML), 40% Polyethylene Glycol 300 (Fujifilm Wako Pure Chemical Industries, Ltd.; 164-09055), 5% Tween™ 80 (Tokyo Chemical Industry Co., Ltd.; T546), and 50% dH 2 The solution was dissolved in 0 to a concentration of 7.2 mg / mL. Mice were immobilized in WPI Mouse Stereotaxic Instruments (World Precision Instruments; 505314) under mixed anesthesia with medetomidine chloride (0.3 mg / kg; Orion Pharma), midazolam (4 mg / kg; Astellas Pharma Inc.), and butorphanol (5 mg / kg; Vetorphale, Meiji Seika Pharma Co., Ltd.). A Nanoliter Glass Capillary (World Precision Instruments; 504949) was connected to a NANOLITER 2020 INJECTOR (World Precision Instruments; NANOLITER 2020) and inserted at the following coordinates: 0.75 mm posterior to bregma, 1.0 mm lateral from the midline, and 1.5 mm ventral from the cortical surface. A total of 1 μL was injected at a constant rate of 50 nL / min. Von Frey tests were performed 3 and 24 hours after administration, and changes in withdrawal thresholds were examined 4 weeks after administration.

[0076] (14) Conditional knockout experiment of astrocyte-specific STAT3 in the chronic phase. Aldh1l1-CreERT2 mice (B6N.FVB-Tg(Aldh1l1-CreERT2)1Khakh / J), in which the recombinant protein Cre is expressed specifically in astrocytes and translocates into the cell nucleus upon administration of tamoxifen, were crossed with STAT3 flox mice (B6.129S1-STAT3tm1Xyfu / J), in which STAT3 is knocked out by the presence of Cre. The resulting mice, Aldh1l1-CreERT2+ / -::STAT3 flox / flox, which possess both genetic mutations, were then induced with thalamic hemorrhage at 9 to 11 weeks of age to generate mice with post-stroke pain. The control group consisted of mice carrying only one of the two gene mutations, Aldh1l1-CreERT2- / -::STAT3 flox / flox. Tamoxifen administration in the control group is unlikely to result in STAT3 knockout. Von Frey tests were performed before thalamic hemorrhage induction and 7, 14, and 21 days after hemorrhage. Animals in which pain induction due to thalamic hemorrhage was confirmed were used for subsequent experiments. Tamoxifen (SIGMA-ALDRICH; T5648) was dissolved in corn oil (SIGMA-ALDRICH; C8297) to a concentration of 5 mg / mL. Immediately before tamoxifen administration, mice were weighed, and 75 μg / g tamoxifen was administered intraperitoneally for 5 days. The von Frey test was performed starting on day 7 after the start of administration, and changes in withdrawal thresholds were examined for 28 days after administration.

[0077] (15) Chronic Phase Experiment of Astrocyte-Specific STAT3 Knockout in the S1 Region of the Cerebral Cortex STAT3 flox mice (B6.129S1-STAT3tm1Xyfu / J), in which STAT3 is knocked out by the presence of Cre, were induced with thalamic hemorrhage at 9-10 weeks of age to generate mice with post-stroke pain. Von Frey tests were performed before induction of thalamic hemorrhage and 1, 4, 7, 11, and 14 days after hemorrhage, and mice in which pain was confirmed to be induced by thalamic hemorrhage were used for subsequent experiments. Mice were immobilized in WPI Mouse Stereotaxic Instruments (World Precision Instruments; 505314) under mixed anesthesia with medetomidine chloride (0.3 mg / kg; Orion Pharma), midazolam (4 mg / kg; Astellas Pharma Inc.), and butorphanol (5 mg / kg; Vetorphale, Meiji Seika Pharma Co., Ltd.). A Nanoliter Glass Capillary (World Precision Instruments; 504949) was connected to a Nanoliter 2020 Injector (World Precision Instruments; Nanoliter 2020), and AAV5-GFAP-GFP-Cre (4.1 × 10 12 The mice were injected with AAV5-GFAP-GFP (4.1 x 10) as a control, at a distance of 0.50 mm posterior to the bregma, 1.5 mm lateral from the midline, and 0.7 and 0.4 mm ventral from the cortical surface. A total of 250 μL was injected at a constant rate of 50 nL / min. After administration, changes in the withdrawal threshold were examined for 14 days. AAV5-GFAP-GFP (4.1 x 10) was also injected as a control. 12 The mice were administered with 1000 or more virus molecules / n.

[0078] 1-2 Experimental Results (1) Effect of Administration of AG490 and AZD1480 on Pain in a Mouse Model of Chronic Post-Stroke Pain. Figure 1 shows the withdrawal thresholds measured by the von Frey test following administration of AG490 and AZD1480 under conditions of post-stroke pain. As is clear from the graph of the control group (TH / vehicle group) in Figure 1, a significant decrease in withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. This symptom persisted throughout the subsequent observation period, with no improvement observed. On the other hand, in the group administered the JAK / STAT inhibitors AG490 and AZD1480 in the chronic phase (21 days after hemorrhage), two weeks after the onset of pain, a significant increase in withdrawal threshold was observed within 48 hours, suggesting pain improvement. This effect persisted throughout the observation period. These results demonstrated that JAK / STAT is involved in pain during the chronic phase of post-stroke pain.

[0079] (2) Effect of Stattic Administration on Pain in Chronic Post-Stroke Pain Model Mice Figure 2 shows the withdrawal threshold measured by von Frey test after Stattic administration under post-stroke pain pathology. As is clear from the graph, pain developed one week after thalamic hemorrhage. This symptom persisted in the control group until the end of the experiment. On the other hand, in the Stattic-administered group, a significant increase in withdrawal threshold was observed within 48 hours, similar to the administration of AG490 and AZD1480, suggesting that pain had improved.

[0080] (3) Effect of BP-1-102 Administration on Pain in a Mouse Model of Post-Stroke Pain in the Chronic Phase Figure 3 shows the results of measurements of the withdrawal threshold following administration of BP-1-102 under post-stroke pain pathology using the von Frey test. As is clear from the graph, a significant decrease in the withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. This symptom persisted for up to three weeks after thalamic hemorrhage, and no improvement was observed in the control group until the end of the experiment. On the other hand, in the group administered the STAT3 inhibitor BP-1-102 in the chronic phase (21 days after hemorrhage), two weeks after the onset of pain, a significant increase in the withdrawal threshold was observed within 48 hours, suggesting that pain had improved. This effect was also sustained throughout the long-term observation period. Furthermore, Figure 4 shows the results of measurements of the withdrawal threshold following administration of BP-1-102 in the ultra-chronic phase. A significant tendency toward improvement in pain was also observed in the group administered BP-1-102 in the ultra-chronic phase (91 days after bleeding), and this effect was maintained throughout the 84-day observation period after administration.

[0081] (4) Effect of AG490 administration on pain in the early stage of thalamic hemorrhage AG490 was administered intraperitoneally once every 3 to 4 days starting on the day after induction of thalamic hemorrhage. The results are shown in Figure 5. The withdrawal threshold was observed for 14 days after thalamic hemorrhage, but no decrease in the threshold was observed, demonstrating that administration of AG490 prevents the onset of pain.

[0082] (5) Effect of Baricitinib Administration on Pain in a Mouse Model of Chronic Post-Stroke Pain. Figure 6 shows the results of measurements of withdrawal thresholds following baricitinib administration under post-stroke pain conditions using the von Frey test. As can be seen from the graph, a significant decrease in withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. In the group administered baricitinib, an existing JAK inhibitor, in the chronic phase (day 29 after hemorrhage) two weeks after the onset of pain, a significant increase in withdrawal threshold was observed within 48 hours, suggesting pain improvement. However, the pain improvement observed with a single dose of 2 μg / g baricitinib was temporary, and pain gradually recurred. Therefore, when 0.2 μg / g baricitinib was administered for five consecutive days, a significant increase in withdrawal threshold was observed again, suggesting pain improvement. Furthermore, the effect of continuous administration persisted throughout the long-term observation period.

[0083] (6) Effect of Fluorocitrate Administration to the S1 Region of the Cerebral Cortex on Pain in Chronic Post-Stroke Pain Model Mice. Figure 7 shows the withdrawal threshold measured by fluorocitric acid administration under post-stroke pain pathology using the von Frey test. As is clear from the graph, a decrease in withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. This symptom persisted until before fluorocitric acid administration. Direct administration of fluorocitric acid (TH / fluorocitrate) to the S1 region of the cerebral cortex on the 21st day after thalamic hemorrhage resulted in a significant increase in withdrawal threshold within 48 hours, suggesting pain improvement. The effect weakened after four days of administration, and pain recurred three weeks later.

[0084] (7) Effect of BP-1-102 administration to the S1 region of the cerebral cortex on pain in a mouse model of chronic post-stroke pain. Figure 8 shows the results of measurements of the withdrawal threshold following administration of BP-1-102 to the S1 region of the cerebral cortex under post-stroke pain conditions using the von Frey test. As is clear from the graph, a significant decrease in the withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. This symptom persisted for up to three weeks after thalamic hemorrhage. In the group administered the STAT3 inhibitor BP-1-102 to the S1 region of the cerebral cortex in the chronic phase (21 days after hemorrhage), a significant increase in the withdrawal threshold was observed within 48 hours after administration, suggesting a pain-suppressing effect.

[0085] (8) Effect of astrocyte-specific CCL2 conditional knockout on pain in chronic post-stroke pain model mice. Figure 9 shows the withdrawal threshold measured by the von Frey test under post-stroke pain pathology following astrocyte-specific CCL2 knockout. As can be seen from the graph, a significant decrease in withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. This symptom persisted for up to three weeks after thalamic hemorrhage, with no improvement observed. Astrocyte-specific CCL2 knockout was performed with tamoxifen for five days starting 21 days after thalamic hemorrhage, and an increase in withdrawal threshold was observed starting seven days after the start of administration. This effect persisted throughout the observation period.

[0086] (9) Effect of intracerebroventricular administration of matrix metalloproteinase 2 (MMP2) selective inhibitor ARP100 on pain in the chronic phase of post-stroke pain model mice. Figure 10 shows the results of measuring the escape threshold by intracerebroventricular administration of an MMP2 selective inhibitor under post-stroke pain pathology using the von Frey test. As is clear from the graph, a significant decrease in the escape threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. When intracerebroventricular administration of ARP100 (TH / ARP100) was performed in the chronic phase after the onset of post-stroke pain, a significant increase in the escape threshold was observed within 48 hours, suggesting that pain had improved. The effect peaked on the third day after administration, and pain recurred 10 days after administration, suggesting that the effect of ARP100 was transient.

[0087] (10) Effect of astrocyte-specific STAT3 conditional knockout on pain in chronic post-stroke pain model mice. Figure 11 shows the results of measurement of withdrawal thresholds due to astrocyte-specific STAT3 knockout under post-stroke pain pathology using the von Frey test. As can be seen from the graph, a significant decrease in withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. This symptom persisted for up to three weeks after thalamic hemorrhage, and no improvement was observed. Astrocyte-specific STAT3 knockout was performed by administering tamoxifen for five days starting 21 days after thalamic hemorrhage, and an increase in withdrawal threshold was observed starting seven days after the start of administration. This effect was also sustained throughout the observation period.

[0088] (11) Experimental study of astrocyte-specific STAT3 knockout in the S1 region of the cerebral cortex in chronic post-stroke pain model mice. Figure 12 shows the results of measurement of withdrawal thresholds in astrocyte-specific STAT3 knockout in the S1 region of the cerebral cortex under post-stroke pain pathology using the von Frey test. As can be seen from the graph, a significant decrease in withdrawal threshold was observed one week after thalamic hemorrhage, indicating the onset of pain. This symptom persisted for up to two weeks after thalamic hemorrhage, and no improvement was observed. Administration of AAV (AAV5-GFAP-GFP-Cre) into the S1 region of the cerebral cortex 14 days after thalamic hemorrhage resulted in a significant increase in withdrawal threshold four days later, suggesting pain improvement. This effect persisted throughout the observation period.

[0089] Research has shown that the aforementioned AG490 has an inhibitory effect on peripheral neuropathic pain (Neural Regen Res. 13(8):1471-1476 (2018); Brain. 134(4):1127-1139 (2011)). However, it is generally accepted that the molecular pathology of neuropathology is completely different between the peripheral nervous system and the central nervous system, and it is not generally expected that molecular biological knowledge from the peripheral nervous system can be applied to the central nervous system, or vice versa. Therefore, it is assumed that the molecular pathology (mechanism) of pain generation between peripheral neuropathic pain and central neuropathic pain is completely different.

[0090] The aforementioned literature on peripheral neuropathic pain (Brain. 134(4):1127-1139 (2011)) reported the results of administering the drug to an animal model of peripheral neuropathic pain, but noted that the effects disappeared promptly (at least three days after administration). In contrast, the experimental results showed that the effects persisted for at least two weeks after administration, demonstrating a significant difference in efficacy. Generally, in research into nervous system disorders, the peripheral and central nervous systems have significant differences in the molecular mechanisms of nerve regeneration and response to injury, and therefore, treatment development is typically conducted by examining these two systems separately. However, the findings obtained in this study suggest that the mechanisms of action of the same drug may differ between peripheral and central neuropathic pain.

Claims

1. A pharmaceutical composition for treating and / or preventing central neuropathic pain, comprising at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor.

2. The pharmaceutical composition of claim 1, comprising a JAK / STAT inhibitor.

3. The pharmaceutical composition according to claim 1, wherein the central neuropathic pain is pain caused by a brain disorder.

4. The pharmaceutical composition according to claim 1, wherein the central neuropathic pain is post-stroke pain.

5. The pharmaceutical composition according to claim 1, wherein the central neuropathic pain is thalamic pain.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the STAT is STAT3.

7. The pharmaceutical composition according to any one of claims 1 to 5, wherein the JAK / STAT inhibitor is at least one selected from the group consisting of a STAT3 SH2 domain inhibitor, a JAK inhibitor, a STAT3 DNA binding domain inhibitor, a double-stranded RNA having an RNAi effect against the JAK or STAT3 gene, and an antisense nucleic acid against the JAK or STAT3 gene.

8. The pharmaceutical composition according to any one of claims 1 to 5, wherein the JAK / STAT inhibitor is at least one selected from the group consisting of a STAT3 SH2 domain inhibitor and a JAK inhibitor.

9. A pharmaceutical composition for the treatment and / or prevention of neuropathic pain, comprising at least one selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor, the administration interval of which is 6 days or more.

10. The pharmaceutical composition of claim 9, comprising a JAK / STAT inhibitor.